Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61P - Specific therapeutic activity of chemical compounds or medicinal preparations › A61P 3 - Drugs for disorders of the metabolism
Patents for A61P 3 - Drugs for disorders of the metabolism (129,789)
10/2001
10/10/2001EP1140784A2 Ion channel modulating agents
10/10/2001EP1140783A1 Ortho-diphenol compounds, methods and pharmaceutical compositions for inhibiting parp
10/10/2001EP1140191A1 Combinations of ileal bile acid transport inhibitors and nicotinic acid derivatives for cardiovascular indications
10/10/2001EP1140190A1 Combinations of ileal bile acid transport inhibitors and bile acid sequestering agents for cardiovascular indications
10/10/2001EP1140189A1 Combinations of ileal bile acid transport inhibitors and fibric acid derivatives for cardiovascular indications
10/10/2001EP1140188A1 Combinations of ileal bile acid transport inhibitors and cholesteryl ester transfer protein inhibitors for cardiovascular indications
10/10/2001EP1140187A1 Combinations for cardiovascular indications
10/10/2001EP1140186A1 Combinations of cholesteryl ester transfer protein inhibitors and fibric acid derivatives for cardiovascular indications
10/10/2001EP1140185A1 Combinations of cholesteryl ester transfer protein inhibitors and bile acid sequestering agents for cardiovascular indications
10/10/2001EP1140184A1 Combinations of cholesteryl ester transfer protein inhibitors and nicotinic acid derivatives for cardiovascular indications
10/10/2001EP1140173A2 Vascular endothelial cell growth factor antagonists and uses thereof
10/10/2001EP1140148A1 Shelf-stable formulation of glucagon-like peptide-1
10/10/2001EP1140145A2 Novel exendin agonist formulations and methods of administration thereof
10/10/2001EP1140134A1 Agent for treating visual cell function disorder
10/10/2001EP1140133A1 Controlled release formulation comprising gnrh-ii
10/10/2001EP1140126A1 A nascent gold based herbal composition
10/10/2001EP1140115A2 Phospholipid complexes of proanthocyanidin a2 as antiatherosclerotic agents
10/10/2001EP1140113A2 Use of bisphosphonates for the prevention and treatment of infectious processes
10/10/2001EP1140084A1 Novel formulation
10/10/2001EP1140083A1 Novel compounds
10/10/2001EP1140082A1 Combination of cerivastatin and fibrates
10/10/2001EP1140079A1 Assays for ligands for nuclear receptors
10/10/2001EP1140076A1 Use of 5ht3-receptor antagonists for the treatment of chronic fatigue syndrome
10/10/2001EP1140070A1 Treatment of conditions with a need for the inhibition of gsk-3
10/10/2001EP1140065A1 Use of gamma-tocopherol and its oxidative metabolite llu-alpha in the treatment of disease
10/10/2001EP1140051A2 Use or tertbutylhydroquinone for lowering blood cholesterol and/or blood triglycerides
10/10/2001EP1140048A2 Methods for treating certain diseases using naaladase inhibitors
10/10/2001EP1140045A2 Homer a new target of treating psychiatric disorders
10/10/2001EP1140036A2 Novel formulations comprising lipid-regulating agents
10/10/2001EP1140033A2 Improved controlled release compositions and method
10/10/2001EP1140027A1 Dosage forms comprising porous particles
10/10/2001EP1140019A1 Aerosol formulations for buccal and pulmonary application
10/10/2001EP1139913A1 Composition and formulations and their use as nociceptic, anti-anxiolytic and anabolic agents
10/10/2001EP1139744A1 Exo-r-mecamylamine formulation and use in treatment
10/10/2001EP1139743A1 Exo-s-mecamylamine formulation and use in treatment
10/10/2001EP1083172A4 N-substituted derivatives of 5-oxyiminobarbituric acid
10/10/2001CN1316995A Hydroxy 2-pipecolate hydroxamide acid derivatives as MMP inhititors
10/10/2001CN1316994A Piperidine derivatives
10/10/2001CN1316991A Azetidine derivatives, preparation and medicines containing them
10/10/2001CN1316908A Neuroprotection
10/10/2001CN1316902A Therapeutic compositions (II)
10/10/2001CN1316249A Nutritive active liquid of scorpion
10/10/2001CN1316248A Nursing liquid for oral cavity of baby
10/10/2001CN1316242A High mechanical stability solid oral dosage form with slow releasing function for active composition
10/10/2001CN1072647C Novel inhibitors of bone reabsorption and antagonists of vitronectin receptors
10/10/2001CN1072645C Novel 2,3,5-trimethyl-4-hydroxy radical-N-acid aniline derivatives and preparation method and use thereof
10/10/2001CN1072504C 肽的应用 Application peptide
10/09/2001US6300375 Administering sodium oxamate for prophylaxis or therapy of diabetes or complications due to diabetes
10/09/2001US6300359 (E)-3-[1-n-Butyl-5-[2-(2-carboxyphenyl)methoxy-4-chlorophenyl]-1H-pyrazol-4-yl]-2-[(5-methoxy-2,3-dihydrobenzofuran-6-yl)methyl]-prop-2-enoic acid monoargininyl salt
10/09/2001US6300334 Thieno[2,3-d]pyrimidine-2,4-diones
10/09/2001US6300310 Amino acid sequence with segments of polypeptides
10/09/2001CA2123223C Means for the modulation of processes mediated by retinoid receptors and compounds useful therefor
10/09/2001CA2082825C Inhibition of viral infection
10/07/2001CA2304906A1 13-hode, a regulator of vascular biocompatibility and an inhibitor of cell hyperplasia
10/06/2001CA2343259A1 A process for producing solid creatine dosage forms and dosage forms obtainable thereby
10/04/2001WO2001073439A1 Docosahexaenoic acid as retinoid x receptor and uses thereof
10/04/2001WO2001073035A1 A METHOD FOR SCREENING FOR AUTOIMMUNE DISEASE BY IDENTIFYING POLYMORPHISMS IN IL-12 p40
10/04/2001WO2001073034A2 Beta-like glycoprotein hormone polypeptide and heterodimer
10/04/2001WO2001073033A2 Anti-angiogenic and anti-tumor properties of matin and other laminin domains
10/04/2001WO2001073029A2 Isolated human g-protein coupled receptors, nucleic acid molecules encoding human gpcr proteins, and uses thereof
10/04/2001WO2001073025A2 Anti-angiogenic and anti-tumor properties of vascostatin and other nidogen domains
10/04/2001WO2001073002A2 Targeted chromosomal genomic alterations with modified single stranded oligonucleotides
10/04/2001WO2001072977A2 Isolated human drug-metabolizing proteins, nucleic acid molecules encoding human drug-metabolizing proteins, and uses thereof
10/04/2001WO2001072960A2 Il-8 receptor antagonists
10/04/2001WO2001072848A1 Glycosaminoglycans derived from the k5 polysaccharide having high anticoagulant and antithrombotic activity and process for their preparation
10/04/2001WO2001072839A2 Human g-protein coupled receptors
10/04/2001WO2001072836A2 G-protein coupled receptors
10/04/2001WO2001072831A2 Immunoregulator
10/04/2001WO2001072829A2 Peptides blocking vascular endothelial growth factor (vegf)-mediated angiogenesis, polynucleotides encoding said peptides and methods of use thereof
10/04/2001WO2001072802A1 A new polypeptide-human amyloid precursor protein-binding protein 14 and the polynucleotide encoding it
10/04/2001WO2001072779A1 Characterization of grp94-ligand interactions and purification, screening, and therapeutic methods relating thereto
10/04/2001WO2001072777A2 Human transcription factors
10/04/2001WO2001072771A2 Insulin and igf-1 receptor agonists and antagonists
10/04/2001WO2001072770A1 Insulin potentiating peptides
10/04/2001WO2001072758A1 Tricyclic protein kinase inhibitors
10/04/2001WO2001072752A2 2,3,4,5-TETRAHYDRO-1H-[1,4]DIAZEPINO[1,7-a]INDOLE COMPOUNDS
10/04/2001WO2001072744A1 N-heterocyclic derivatives as nos inhibitors
10/04/2001WO2001072737A1 Triarylimidazole derivatives as cytokine inhibitors
10/04/2001WO2001072728A2 Novel piperazine derivatives
10/04/2001WO2001072706A1 Synthesis of [r-(r*,r*)]-2-(4-fluorophenyl)-beta,delta-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1h-pyrrole-1-heptanoic acid hemi calcium salt (atorvastatin)
10/04/2001WO2001072703A1 Amidino compound and salts thereof useful as nitric oxide synthase inhibitors
10/04/2001WO2001072702A2 Amidino compounds useful as nitric oxide synthase inhibitors
10/04/2001WO2001072701A1 Ceramide derivatives and method of use
10/04/2001WO2001072692A1 Malonamic acids and derivatives thereof as thyroid receptor ligands
10/04/2001WO2001072688A2 Method for preparing (2s,3r,4s)-4-hydroxyisoleucine and analogues thereof
10/04/2001WO2001072328A2 Methods of treating diseases with activated protein c
10/04/2001WO2001072325A1 Methods of blocking tissue destruction by autoreactive t cells
10/04/2001WO2001072316A1 Ayurvedic composition for diabetes
10/04/2001WO2001072308A1 Composition and method for intervening neuronal death using sulfasalazine
10/04/2001WO2001072290A2 Method for the improvement of islet signaling in diabetes mellitus and for its prevention
10/04/2001WO2001072279A2 Medical emulsion for lubrication and delivery of drugs
10/04/2001WO2001072136A1 Sterol ester compositions
10/04/2001WO2001047878A8 Substituted pyrrole mannich bases to combat pain and allergic reactions
10/04/2001WO2001046144A8 New modulators of dopamine neurotransmission
10/04/2001WO2001019828A3 Kinase inhibitors as therapeutic agents
10/04/2001WO2001016319A3 Compositions and methods for the treatment of immune related diseases
10/04/2001WO2001013957A3 Enhancing drug delivery across and into epithelial tissues using oligo arginine moieties
10/04/2001WO2000047625A9 Humanized immunoglobulin reactive with b7 molecules and methods of treatment therewith
10/04/2001WO2000039279A9 Dna encoding a human melanin concentrating hormone receptor (mch1) and uses thereof
10/04/2001WO2000032634A9 Humanized antibodies to gamma-interferon
1 ... 1039 1040 1041 1042 1043 1044 1045 1046 1047 1048 1049 1050 1051 1052 1053 1054 1055 1056 1057 1058 1059 ... 1298